

### State of Oklahoma **SoonerCare**

Sooner <b>Select</b>		<b>♥</b> aetna
----------------------	--	----------------

## **Continuous Glucose Monitor (CGM) Prior Authorization Form**

System Information			
Please select CGM:  □ Dexcom® G6 □ Dexcom® G7 □ FreeStyle® Libre □ FreeStyle® Libre 2 □ FreeStyle® Libre 3 Please note: For CGM product continuation requests, please only list NDCs needed.  Please provide NDCs: Receiver/Reader NDC: ————————————————————————————————————	Please indicate quantity:  Sensor: qty: perdays  Transmitter: qty: perdays		
Billing Provider Information			
Pharmacy NPI: Pharmacy Name:			
Fill Date: Pharmacy Phone: Pharm	acy Fax:		
Prescriber Information			
Prescriber NPI: Prescriber Name:			
Prescriber Phone: Prescriber Fax:			
Page 1 of 2 - Please complete and return all pages. Failure to complete all pages will result in processing delays.  For Initial Authorization:  1. Please indicate diagnosis:  1. Type I diabetes mellitus (T1DM) meeting the criteria of American Diabetes Association (ADA)  1. Standards of Medical Care in Diabetes, 2021  1. Type 2 diabetes mellitus (T2DM) meeting the criteria of ADA Standards of Medical Care in Diabetes, 2021  1. Gestational Diabetes mellitus meeting the criteria of ADA Standards of Medical Care in Diabetes, 2021  1. Pregnant with a medically documented diagnosis of T1DM  1. Other:  2. Date of diagnosis:			
<ul> <li>3. Is the member currently receiving insulin therapy? Yes No</li> <li>A. If "No" to Question 3 and member is under 21 years of age, does problematic hypoglycemia with documentation of at least one or Recurrent (more than one) level 2 hypoglycemic events (glup persist despite multiple (more than one) attempts to adjust rediabetes treatment plan. If yes, please provide the following Glucose: mg/dL Date Taken: Glucose:</li> <li>History of one level 3 hypoglycemic event (glucose &lt;54mg/daltered mental and/or physical state requiring third-party associated including date and assistance</li> </ul>	f the following: cose <54mg/dL (3.0mmol/L)) that nedication(s) and/or modify the :mg/dL Date Taken: dL (3.0mmol/L)) characterized by sistance for treatment of hypogly-		

Fax completed prior authorization request form to 888-601-8461 or submit Electronic Prior Authorization through CoverMyMeds® or SureScripts. All requested data must be provided. Incomplete forms or forms without the chart notes will be returned. Pharmacy Coverage Guidelines are available at

AetnaBetterHealth.com/Oklahoma.

**CONFIDENTIALITY NOTICE** 

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.

Pharm - 139 6/1/2023



# 

# State of Oklahoma uthority Oklahoma Health Care Authority Continuous Glucose Monitor (CGM) Prior Authorization Form

Member Name: \_\_\_\_\_ Date of Birth: \_\_\_\_ Member ID#:

Clinical Information		
	ge 2 of 2 - Please complete and return all pages. Failure to complete all pages will result in processing	
	itial Authorization, continued:	
4.	Has the treating practitioner had an in-person or telehealth visit with the member and/or family in the 6 months prior to ordering the CGM to evaluate their diabetes control and determined that the above criteria are met? Yes No	
5.	criteria are met? Yes No Has the member and/or family member participated in age-appropriate diabetes education, training, and support prior to beginning CGM? Yes No	
6.	For FreeStyle Libre 3, is the member capable and willing to use the FreeStyle Libre 3 mobile app and follow the FreeStyle Libre 3 <i>Instructions for Use</i> ? Yes No	
7.	For FreeStyle Libre 3, has the member ensured the FreeStyle Libre 3 mobile app is compatible with the member's specific smartphone? Yes No	
Fo	or Continued Authorization:	
	Has member been seen at least every 6 months following the initial prescription of the continuous glucose monitoring (CGM), by the CGM prescriber, to assess adherence to their CGM regimen and diabetes treatment plan? Yes	
2.	Has member received ongoing instruction and regular evaluation of technique, results, and their ability to use data from self-monitoring of blood glucose to adjust therapy? Yes No	
3.	Do the member's prescriber records include documentation (i.e. trend graphs or CGM reports) demonstrating member's daily use of the CGM? Yes  No	
4.	Does the member need an additional receiver/reader? Yes No	
5.	If an additional receiver/reader is being requested, please provide information to support why the member is unable to use the previously dispensed product:	
6.	If the receiver/reader is malfunctioning, has the manufacturer been contacted for product replacement? Yes No	
Ac	Iditional information:	
	escriber Signature: Date:	
	y signature, the physician confirms the criteria information above is accurate and verifiable in patient cords.) Please do not send in chart notes. Specific information/documentation will be requested if necessary.	

Fax completed prior authorization request form to 888-601-8461 or submit Electronic Prior Authorization through CoverMyMeds® or SureScripts. All requested data must be provided. Incomplete forms or forms without the chart notes will be returned. Pharmacy Coverage Guidelines are available at AetnaBetterHealth.com/Oklahoma.

#### CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.

Pharm - 139 6/1/2023

Please complete and return all pages. Failure to complete all pages will result in processing delays.